The latest Impact Factors have been released and are updated in our site!

Not a Current Subscriber?

Subscribe Now

4726 Journals
3145 Congresses
7800+ Unique Records


Title Abbreviation
Electronic ISSN
Advanced Practice Nurses, Allergists, Allied Health Professionals, Anesthesiologists, Cardiologists, Caregivers, Critical Care Nurses, Critical Care Physicians, Dermatologists, Emergency Nurses, Emergency Physicians, Endocrinologists, Family Practice Physicians, Gastroenterologists, General Practitioners, Geriatricians, Gynecologists, Hematologists, Hepatologists, Hospice Nurses, Infectious Disease Specialists, Internists, Neonatologists, Nephrologists, Neurologists, Nurse Practitioners, Obstetricians, Oncologists, Ophthalmologists, Pain Specialists, Pathologists, Patients, Pediatricians, Perinatologists, Pharmacists, Pharmacologists, Physicians, Primary Care Physicians, Psychiatrists, Pulmonologists, Radiation Oncologists, Researchers, Rheumatologists, Scientists, Urologists
Drugs promotes optimum pharmacotherapy by providing a programme of review and original research articles on the most important aspects of clinical pharmacology and therapeutics. The Journal includes: - Leading/current opinion articles providing an overview of contentious or emerging issues. - Definitive reviews of drugs and drug classes, and their place in disease management. - Therapy in Practice articles including recommendations for specific clinical situations. - High-quality, well designed, original clinical research. - Adis Drug Evaluations reviewing the properties and place in therapy of both newer and established drugs. - AdisInsight Reports summarising development at first global approval. Additional enhanced features (including slide sets, videos and animations) can be published with articles; these are designed to increase the visibility, readership and educational value of the journal’s content. In addition, articles published in Drugs may be accompanied by plain language summaries to assist readers in understanding important medical advances. All manuscripts are subject to peer review by international experts. Letters to the editor are welcomed and will be considered for publication. Stay up to date with the latest developments in therapeutics by reading the world’s most respected source of authoritative drug information. For over 40 years Drugs has been the definitive journal of drugs and therapeutics, promoting optimum pharmacotherapy by publishing reviews and original research authored by leading international clinicians and researchers to support clinical decision-making. Through a rigorous and comprehensive program of peer-reviewed evaluations, Drugs provides detailed and objective analysis covering the full spectrum of new and established drug therapies in all disease areas. The journal Also offers the ability to create digital features as well as host them. This journal offers a VIP service (i.e. fast-track) for suitable papers. This service offers a customized schedule for submission to online publication in 30 days. Please contact and for further details of this service. There is a fixed fee for this service (no fee for rejected manuscripts).
Sponsoring Association(s)
No associations affiliated with this journal
Publisher Name
Adis, part of Springer Nature
To see more details about Drugs, Subscribe Now!
Impact Factor JCR Categories/Rank Electronic Circulation Submission to Acceptance Acceptance to Online Publication Rejection Rate Frequency Journal Contact Author Submission Guidelines


"PubsHub [Journals & Congresses] is an indispensable tool when trying to find the perfect home for a manuscript. It is an unbeatable aid when it comes to wise and efficient journal selection."
– Kait G
Editorial-Project Editor
"It’s useful for establishing publication timelines, communicating them to management and setting expectations accordingly"
– Michael K.
Medical Communications Leader
"…a gold mine of information for clinicians and scientists who are trying to determine where to publish their research."
- Weill Cornell Medical Library